Proteomic analysis reveals co-ordinated alterations in protein synthesis and degradation pathways in LRRK2 knockout mice

Laura Pellegrini\textsuperscript{1,2}, David N Hauser\textsuperscript{1}, Yan Li\textsuperscript{3}, Adamantios Mamais\textsuperscript{1}, Alexandra Beilina\textsuperscript{1}, Ravindran Kumaran\textsuperscript{1}, Andrea Wetzel\textsuperscript{2}, George Heaton\textsuperscript{1,2}, Iakov Rudenko\textsuperscript{4}, Mor Alkaslasi\textsuperscript{1}, Natalie Ivanina\textsuperscript{1}, Heather L Melrose\textsuperscript{5}, Mark R Cookson\textsuperscript{1} \dagger and Kirsten Harvey\textsuperscript{2} \Ast\dagger

\textsuperscript{1}Cell Biology and Gene Expression Section, Laboratory of Neurogenetics, National Institute of Aging, National Institutes of Health, 35 Convent Drive, Bethesda, MD 20892-3707, USA
\textsuperscript{2}Department of Pharmacology, UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK
\textsuperscript{3}Mass-spectrometry facility, National Institute of Neurological Diseases and Stroke, National Institutes of Health, 35 Convent Drive, Bethesda, MD 20982-3721, USA
\textsuperscript{4}Department of Neurology, SUNY at Stony Brook, Health Science Center, T12-020, Stony Brook, New York, 11794-8121, USA
\textsuperscript{5}Department of Neuroscience, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville FL 32224, USA

\dagger These authors have contributed equally to this work

*To whom correspondence should be addressed at: UCL School of Pharmacy 29-39 Brunswick Square, London WC1N 1AX, UK, telephone: +44 020 7753 5888, email: kirsten.harvey@ucl.ac.uk

© The Author(s) 2018. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract

Mutations in leucine-rich repeat kinase 2 (LRRK2) segregate with familial Parkinson’s disease (PD) and genetic variation around LRRK2 contributes to risk of sporadic disease. Although knockout of LRRK2 or knock-in of pathogenic mutations into the mouse germline does not result in a PD phenotype, several defects have been reported in the kidneys of LRRK2 knockout mice. To understand LRRK2 function in vivo, we used an unbiased approach to determine which protein pathways are affected in LRRK2 knockout kidneys. We nominated changes in cytoskeletal-associated proteins, lysosomal proteases, proteins involved in vesicular trafficking and in control of protein translation. Changes were not seen in mice expressing the pathogenic G2019S LRRK2 mutation. Using cultured epithelial kidney cells, we replicated the accumulation of lysosomal proteases and demonstrated changes in subcellular distribution of the cation-independent mannose-6-phosphate receptor. These results show that loss of LRRK2 leads to co-ordinated responses in protein translation and trafficking and argue against a dominant negative role for the G2019S mutation.
Introduction

Variation in the Leucine-rich repeat kinase 2 (LRRK2) gene account for a proportion of the genetic risk of Parkinson’s disease (PD). Causative mutations in the LRRK2 gene occur in multiple families (1–4) and genome-wide association studies (GWAS) nominated the LRRK2 locus as contributing to sporadic PD risk (5–7).

$LRRK2$ encodes a large protein containing kinase and GTPase enzymatic regions, which contain pathogenic mutations, surrounded by multiple protein-protein interaction domains (8). Pathogenic mutants are more active than wild type LRRK2 in vitro and in cellular assays (9–11). As homozygous and heterozygous patients carrying the G2019S mutation have similar risk of developing PD and similar disease progression (12–14), G2019S is a true dominant allele. Potential mechanisms include a gain of normal function, a neomorphic function not seen in the wild type protein or a dominant negative effect. Distinguishing whether mutant LRRK2 is pathogenic via higher or lower activity is critically important as kinase inhibitors are being developed as therapeutic agents for PD (15).

LRRK2 is implicated in vesicular trafficking (16–19), perhaps due to phosphorylation of Rab GTPases, key regulators in membrane trafficking (9, 20). LRRK2 is also involved in the regulation of cytoskeletal dynamics (21–24), including an interaction with $\beta$-tubulin isoforms (21). Finally, LRRK2 has been proposed to influence protein translation (25–28) although the precise mechanism(s) involved have not been delineated. Whether the proposed effects on protein translation are related to vesicular and/or cytoskeletal events is uncertain.

Transgenic or knockout (KO) mouse models do not consistently recapitulate the primary PD pathologies, including loss of dopamine neurons in the substantia nigra (18, 29–31). However, multiple groups have reported that loss of LRRK2 causes age-dependent pathological alterations in kidneys (18, 29, 30, 32), potentially due to high expression of LRRK2 relative to LRRK1 (30). LRRK2-KO kidneys have altered texture, an increase in apoptotic cell death and inflammation (18), and an accumulation of lipofuscin (18, 29, 30, 32) that may occur due to altered lysosomal function (18, 29). Some of LRRK2-KO phenotypes are reproduced in kinase dead LRRK2 knock-in mice or mice exposed to kinase inhibitors, but not in kidneys from homozygous G2019S knock-in mice (29).

Collectively, these observations suggest that LRRK2-KO kidneys can be used to investigate the
normal function of this protein. Here, we performed two proteomic screens comparing LRRK2 deficient or LRRK2 G2019S knock-in mouse kidneys with age-matched controls to address endogenous LRRK2 function \textit{in vivo}. Our findings demonstrate that, first, LRRK2 deficiency results in proteome changes showing enrichment in proteins involved in cytoskeletal stability, lysosomal degradation and protein translation and, secondly, that the G2019S mutant does not mimic the KO state. Therefore, loss of LRRK2 influences multiple cellular pathways in a co-ordinated manner and G2019S does not result in overlapping proteomic changes.

\section*{Results}

\textit{Differentially expressed vesicular trafficking and protein translation proteins in LRRK2-KO kidneys}

To survey proteomic differences between LRRK2-KO mice and wild type littermate controls, we performed iTRAQ with ultracentrifugated fractions, a 10K supernatant enriched in cytosolic proteins and a 10K pellet enriched in microsomal proteins. This fractionation step was performed with the intent to reduce sample complexity and improve peptide coverage in our iTRAQ screen. We focused on changes in protein abundance as a measure of differential expression to provide an unbiased and quantitative insight into physiological processes such as protein synthesis and degradation potentially affected by LRRK2.

We compared each fraction from each animal against a common reference pool, with both genotypes distributed across different iTRAQ runs (Figure 1A). To confirm sample enrichment, we performed immunoblots to detect the abundance of specific protein markers for each fraction. As expected, late-endosome and lysosome markers, the small GTPase Rab7 and the membrane protein LAMP1, were significantly enriched in the 10K pellets compared to the 10K supernatants (Figure 1B), although Rab7 was also detected in 10K supernatants. In addition, the cytosolic protein GAPDH was enriched in the 10K supernatant (Figure 1B). As the goal of this enrichment was to improve protein detection rather than the generation of more defined pure fractions, these samples were used for the following proteomic experiments.

In the 10K supernatants samples, we identified 700 (Run 1) and 600 (Run 2) unique proteins, with 504 common proteins. In the 10K pellets, 1500 (Run 1) and 1800 (Run 2) unique proteins were detected, with 1187 shared hits. 375 of the proteins were detected in both fractions. In the 10K supernatants, 23 proteins...
differed significantly in abundance between LRRK2-KO and controls, with most proteins showing higher
detection in the KO animals compared to wild type (Figure 1C). We further identified 25 significantly
different proteins in the 10K pellets, of which 5 were also significantly different in the 10K supernatants
(Figure 1D). Unsupervised hierarchical clustering of differential proteins separated genotypes in both 10K
supernatants and 10K pellets (Figures 1E, 1F). We classified differentially abundant proteins using gene
ontogeny (GO) analysis (Figure 2). Consistent with previous findings (18), we found significant enrichment
in categories related to protein degradation (Figure 2), including the GO:Cellular compartment terms lytic
vacuole and lysosomal lumen (Figures 2, S1B). These categories were populated by multiple lysosomal
enzymes including cathepsin D (Ctsd), legumain (Lgmn), dipeptidyl peptidase 7 (Dpp7) and galactosidase
beta 1 (Glb1), all found in higher abundance in LRRK2-KO compared to wild type mice (Figure 1C, Figure
1D).

Cytoskeletal proteins were also differentially expressed in KO kidneys. Lower levels of Tubb4b and
gephyrin (Gphn) were noted in LRRK2-KO 10K pellets (Figures 1D, 1F), while coronin 1C (Coro1c),
protein kinase C and casein kinase substrate in neurons protein 1 (Pacsin2) and septin 9 (Sept9), were
significantly higher in the LRRK2-KO 10K supernatants compared to controls (Figures 1C, 1E). Many of
these proteins were also represented in the GO:Cellular compartment term “extracellular exosome” (p =
3.13 x 10^-12 (Figures 2, S1B).

A third set of proteins related to “initiation of mRNA and protein translation” was differentially
abundant in LRRK2-KO 10K pellets (Figure 2, S1D). Among these, heterogeneous nuclear
ribonucleoprotein K (Hnrnpk) and elongation factor 1-gamma (Eef1g) were higher in the 10K supernatants
of KO animals compared to controls, while the eukaryotic translation initiation factor 4 subunit G3
(Eif4g3) and related proteins Eif5, Eif3l were lower in KO 10K pellets.

In summary, we found clear significant differences in abundance of proteins functioning in synthesis and
catabolic function. Most of these proteins belonged to three main categories, proteins important for protein
translation, cytoskeletal function and lysosomal function.

**G2019S knock-in mutant kidneys do not show detectable differences in protein expression levels**

Collectively, the above data nominate a series of proteins that respond to Lrrk2 deficiency in vivo.
To address effects of a PD associated Lrrk2 mutation, we performed a second iTRAQ experiment using LRRK2-G2019S knock-in animals. We identified 729 unique proteins in the 10K supernatants (Figure 3A) and 785 unique proteins in the 10K pellets (Figure 3B). However, we did not detect any significant differences in protein abundance between genotypes in either fraction (Figures 3A, 3B). Given that the number of proteins detected in each experiment varied and that iTRAQ ratios have a compressed dynamic range (33), we were concerned that the apparent negative result in the G2019S experiment was due to an underestimate of true differences. We therefore directly compared the KO and G2019S experiments for those proteins detected in all experiments for each fraction. Using hierarchical clustering, we found that the KO samples separated from both G2019S knock-in and wild type samples but knock-in and WT did not (Figures 3C, 3D). No correlation was found between LRRK2-G2019S knock-in protein abundance in comparison to wild type for 10K supernatants (Figure 3E; Pearson’s correlation between log2 fold differences, $R=0.0496$, $p=0.389$, n=304 proteins) or pellets (Figure 3F; Pearson’s correlation between log2 fold differences, $R=-0.0445$, $p=0.308$, n=527 proteins).

We considered whether the lack of effect of the G2019S genotype might result from temporal separation of experiments. To address this, we re-ran KO 10K supernatants against wild type controls as in the first iTRAQ experiment. Again, we saw similar, significant differences in genotype (Figure S2A) sufficient to separate genotypes using hierarchical clustering (Figure S2B). Moreover, there was a positive correlation between the Log2 ratios of KO to wild type proteins in the two runs (Figure S2C) but again not with the G2019S knock-in proteins (Figure S2D). Overall, these results show that the G2019S allele has no distinguishable effect on the proteome compared to the strong effect on protein abundance observed upon Lrrk2 knockout under the used experimental conditions.

Validation of iTRAQ results confirms deregulation of proteins important for translational, lysosomal and cytoskeletal function

To validate these results, immunoblots were performed for candidate proteins using the same protein extracts from the initial 12-month old cohort of animals (n=5 per group) and G2019S knock-in animals for direct comparison to LRRK2-KO kidneys (Figures 4A-4E). We first confirmed the expected absence of LRRK2 in both LRRK2-KO enriched fractions (Figures 4A, 4B). In our proteomic analysis, cathepsin D
was significantly higher in the LRRK2-KO 10K supernatants compared to controls. Immunoblot results confirmed higher levels for both mature (p = 0.0001, Bonferroni post-hoc test from one-way ANOVA, n=5 animals) and precursor (p = 0.0004) forms of cathepsin D in LRRK2-KO (Figures 4A, 4C). There were no differences between wild type and LRRK2-G2019S for cathepsin D (Figures 4A, 4C). Similarly, higher levels of the lysosomal protease legumain were confirmed in both fractions by immunoblot (p < 0.0001; Figures 4A, 4C). Legumain was not detected in the G2019S iTRAQ screen, but immunoblot of the LRRK2-G2019S enriched fractions did not detect any difference in legumain expression compared to controls (Figures 4A, 4C, 4D). Cathepsin D mature (p = 0.0006) and precursor forms (p = 0.0014) were also higher in the LRRK2-KO, but not in LRRK2-G2019S, 10K pellets compared to wild type controls (Figures 4B, 4D). Legumain was nominated as increased in LRRK2-KO 10K pellets by iTRAQ (p adjusted = 0.049), which was confirmed using immunoblotting in KO samples (p<0.05) but not in G2019S knock-in samples (Figures 4B, 4D).

Our iTRAQ results indicated that NatA Auxiliary Subunit 15 (Naa15), a protein important for cotranslational protein acetylation that may also interact with the cytoskeleton (34), was lower in LRRK2-KO 10K pellets and higher in LRRK2-KO 10K supernatants compared to controls (Figures 1B, 1C). We confirmed lower protein levels of Naa15 in 10K pellets (p = 0.0003) (Figure 4B, 4D) but found that Naa15 expression was also lower in 10K supernatants (p = 0.011) (Figures 4A, 4C). Naa15 protein expression was significantly increased in G2019S 10K supernatants, compared to LRRK2-KO or wild type samples (p < 0.0001) (Figures 4A, 4C). Two additional proteins with importance for protein translation, elongation factor 1-gamma (Eef1g) and heterogeneous nuclear ribonucleoprotein K (Hnrnpk), both showed a significant increase in LRRK2-KO but no change in G2019S knock-in tissue (Figures 4A, 4C).

We next examined a series of cytoskeleton-associated proteins. The actin binding protein coronin 1C (Coro1c) was detected as more abundant in LRRK2-KO mice compared to controls in our iTRAQ experiments. A 53kDa band corresponding to coronin 1C was decreases in the LRRK2-KO kidneys but a lower molecular weight band (37kDa) was significantly increased by LRRK2 deficiency (p < 0.001) (Figures 3A-3D). We therefore infer that the lower band is likely to correspond to the unique peptide detected as increased in the iTRAQ dataset. The microtubule-associated protein gephyrin (Gphn), significantly decreased in LRRK2-KO 10K pellets in iTRAQ, was validated in 10K supernatants (p <
0.0001) and pellets (p = 0.0025) (Figures 4A-4D). To address the observed changes in tubulin associated proteins including Tubb4b further and given the lack of specific reliable anti-Tubb4b antibodies, we investigated differences in total and acetylated tubulin in our samples. A significant increase in acetylated-tubulin adjusted to $\alpha/\beta$-tubulin was detected in 10K supernatants from KO animals compared to wild type (p = 0.0171). Additionally, $\alpha/\beta$-tubulin, normalized expression levels were significantly lower in LRRK2-KO 10K supernatants compared to controls (p = 0.0002) (Figures 4A-4D). No significant difference in gephyrin, acetylated or total tubulin was detected between G2019S and wild type animals.

To investigate whether changes could be observed in neural tissue, immunoblots were performed on cerebral cortex, hippocampus and striatum from the same 12-month-old mice. No significant difference was detectable between LRRK2-KO and wild type mice for most of the proteins tested (Figure S3) with the exception of gephyrin, where expression levels were lower in LRRK2-KO hippocampus (p<0.05, t-test, n=5 animals) but no difference was shown in other brain regions tested (Figures S3E, S3F). Therefore, the effects of LRRK2 deficiency on protein expression levels in the brain are more modest than those in the kidney.

These results validate 11 out of 12 nominated protein expression differences between LRRK2-KO and wild type kidneys, with the exception being Naa15 in the 10K supernatants. Overall, we found that fold differences between genotypes were larger using immunoblotting than with iTRAQ (Figure 4E), consistent with the issue of ratio compression in iTRAQ experiments (33). We did not detect differences between wild type and G2019S knock-in animals apart from Naa15, which was more abundant in the 10K supernatants, in contrast to KO lysates.

Additional biological validation reveals age-dependent changes in LRRK2-KO kidneys

Alterations in LRRK2-KO kidneys show age-dependent effects (18). To test whether this was true for all candidate proteins we examined a series of independent cohorts of LRRK2-KO animals at different ages. Given that we were able to detect our proteins of interest by immunoblot without enrichment and we did not observe significant protein migration between enriched fractions, we performed immunoblots on total kidney homogenates to avoid any possible protein loss.

No significant differences were observed in kidney lysates from LRRK2-KO and control newborn
(P0) mice \( (n=6 \text{ animals per genotype}) \) in any of the markers examined except for a significant decrease in Hnrrnpk levels in LRRK2-KO kidneys (Figures 5A, 5F, S4). In 1-month old animals \( (n=6) \), we observed a small but significant accumulation of the mature form of cathepsin D, an equally small but significant increase in Hnrrnpk and decrease in Eef1g, and significantly lower levels of \( \alpha / \beta \)-tubulin and a substantial increase in acetylated-tubulin in KO animals compared to wild type. No changes were detected for legumain, Naa15, coronin 1C, gephyrin (Figures 5B, S4).

In an independent cohort of 9-month old mice \( (n=3,) \), cathepsin D and legumain levels were significantly higher in LRRK2-KO kidney homogenates compared to wild type animals. Naa15 protein levels were significantly decreased in the LRRK2-KO samples and a similar level of coronin 1C was noted as seen in the initial cohort used for proteomics. We also detected significantly lower levels of \( \alpha / \beta \)-tubulin, together with higher levels of tubulin-acetylation (Figures 5C, S4). We also confirmed similar differences in kidney homogenates from the 12-month old mouse cohort \( (n=5) \) used for iTRAQ experiments (Figures 5D, 4, S4).

Collectively, these results show that an increase in lysosomal proteases together with a decrease in total tubulin accompanied by an increase in tubulin acetylation are detectable throughout most of the time points and therefore are the most consistent. Changes in translational proteins were found to be the least consistent over time. Of the nominated differences between genotypes, at the earliest ages there were changes in Hnrrnpk and Eef1g, accumulation of mature cathepsin D, and loss of \( \alpha / \beta \)-tubulin accompanied by an increase in acetylated tubulin. These results suggest that the primary responses to Lrrk2 deficiency in the kidney include translational, lysosomal and cytoskeletal changes but that changes over time affect more consistently in particular lysosomal hydrolases and cytoskeletal proteins.

**Accumulation of endo-lysosomal clusters in LRRK2-KO kidneys**

To further characterize the LRRK2-KO lysosomal phenotype, we performed immunofluorescent staining of kidney sections from 6-month old animals. As expected, LRRK2-KO kidneys were larger, heavier and darker in color than their wild type counterparts (Figures S5A, S5B). The most prominent observed changes were enlarged and more numerous cathepsin D positive punctae in the proximal tubules of LRRK2-KO kidneys (Figure 6A, 6F, 6G). To better discern cathepsin D positive vesicles, we used...
super-resolution microscopy (Figure 6B). Cathepsin D partially colocalized with the late-endosomal/lysosomal marker LAMP1 in WT animals but showed more distinct localization to the lysosomal membrane in KO animals (Figure 6B). LAMP1 positive structures appeared also significantly enlarged in LRRK2-KO (Figure 6A, 6H). Analysis of cathepsin D and LAMP1 show an increase in colocalization between the two markers in LRRK2-KO kidneys indicating an accumulation of cathepsin D in the endo-lysosomal compartment (Figure 6D).

Lysosomal proteases such as cathepsin D are synthesized in the ER as inactive precursors, recognized by mannose-6-phosphate receptor (M6PR) and transported via the trans-Golgi network (TGN) and sorting endosomes to lysosomes where they undergo maturation by pH-dependent proteolytic cleavage (35). We hypothesized that LRRK2 deficiency affects cathepsin D protein sorting via its receptor. To test this hypothesis we analyzed cathepsin D and cation-independent M6PR (CI-M6PR) by immunofluorescence in kidney sections (Figure 6C). We observed an increase in colocalization between cathepsin D and CI-M6PR in LRRK2-KO kidneys (Figure 6E) suggesting a scenario in which cathepsin D and its receptor are accumulating in an endo-lysosomal compartment and fail to recycle back to the Golgi. To further investigate this hypothesis, we probed 12 month-old kidney extracts for LAMP1 and M6PR by immunoblot. We observed a significant increase in M6PR in LRRK2-KO kidney extracts (Figure 6I, 6J). Surprisingly, no significant differences in LAMP1 levels were detected although we can observe an increasing trend in the KO (Figure 6I, 6K). Taken together, these results suggest that cathepsin D trafficking is dysregulated in LRRK2 knockout kidneys.

**Primary kidney cells show that lysosomal dysregulation is a primary consequence of LRRK2 deficiency**

To investigate the possibility of dysregulated cathepsin D trafficking further and gain more in depth inside into the most reproducible and earliest increase in protein abundance observed in our animal cohorts, we cultured epithelial cells from the kidney cortex from wild type and LRRK2-KO animals.

As in vivo, cells lacking LRRK2 had fewer but larger cathepsin D positive clusters compared to wild type controls, resulting in an overall accumulation of cathepsin D (Figures 7A-7D). We did not detect a significant difference in LAMP1 fluorescence intensity (Figure S7). This is in contrast to what was observed in kidney histological sections in LRRK2-KO (Figure 6). The lack of a significant increase in
LAMP1 between genotypes in cells is in accordance with cathepsin D increase in precursor but not in the mature form (Figure 7C). To further investigate this difference we measured the colocalization of cathepsin D with LAMP1 in primary kidney cells (Figure S7). Here we observed a decrease in colocalization between the two markers in LRRK2-KO cells. These data suggest that in our cell model the lysosomal hydrolase cathepsin D is improperly processed and accumulates in pre-lysosomal compartments.

In our attempt to provide a mechanistic explanation for this accumulation, we next asked whether we could observe the same differences in the CI-M6PR trafficking pathway reported in kidney sections (Figure 6C). We observed enlarged, and more dispersed CI-M6PR-positive vesicles in primary LRRK2-KO cells compared to wild type cells (Figures 7E, 7F) suggesting that defects in vesicle trafficking may be important in LRRK2 effects on lysosomal proteases. To further test this hypothesis, we inhibited lysosomal acidification using bafilomycin-A1 (Figures S6A, S6B). As expected, mature cathepsin D levels were decreased in response to bafilomycin-A1, whereas we observed a decrease in the precursor form of cathepsin D and increase of pre-pro cathepsin D together with an increase in LC3-II. Interestingly, the differences between genotypes were abolished upon bafilomycin treatment, suggesting that trafficking rather than expression of cathepsin D is the critical regulator of cathepsin D levels (Figures S6A, S6B). Supporting this idea, we further confirmed that cathepsin D mRNA expression does not differ between genotypes (Figures S6C-S6G). Another possible interpretation of the results obtained after bafilomycin treatment is that we could observe an increase in cathepsin D secretion, previously reported upon treatment with this lysosomal inhibitor (36).

Defects in cathepsin D trafficking have been reported in cells expressing the dominant negative form of Rab7 (37) showing a collapse of the endosomal system typified by swollen endosomes positive for both endosomal and lysosomal markers. To test whether the defective trafficking of cathepsin D in LRRK2-KO cells is also coupled with defective endo-lysosomal organization we quantified colocalization between cathepsin D and the early endosomal localized CI-M6PR (Figures 7G, 7H). As expected in wild-type cells the two proteins showed partial colocalization onto small (500nm-1 μm) punctate endosomes. However, in LRRK2-KO cells we observed a significant increase in the colocalization between the two markers indicating a fundamental defect in the organization of the endo-lysosomal system. Therefore, in both kidney cells and tissue we observed an increase in colocalization between cathepsin D and the CI-M6PR.
suggesting impaired receptor recycling in the absence of LRRK2. These results show that deficiencies in the organization of the endo-lysosomal system represent a primary event in response to loss of LRRK2.
Discussion

Understanding the physiological function of LRRK2 has implications for nominating biological processes relevant to PD and may be important for predicting safety and tolerability of LRRK2 kinase inhibitors if these compounds proceed to clinical trials. Here, we show that genetic ablation of LRRK2 is associated with altered levels of proteins related to lysosomal, cytoskeletal and protein translation pathways in vivo. In cells, we find enhanced trafficking of the CI-M6PR to lysosomes, potentially identifying a very early consequence of LRRK2 inhibition resulting in the observed accumulation of lysosomal proteases over time. By contrast, mice harboring the G2019S allele do not display any overt phenotypic difference from control mice and show only minimal changes in protein expression compared to the clear changes in LRRK2-KO mouse kidneys. Our observations showing no clear effects on protein abundance argue against a simple dominant negative mechanism for the G2019S mutation in PD kidneys and/or brain.

Prior studies of LRRK2-KO mice have identified multiple abnormalities in kidneys (30, 38, 39). Here, we have extended past approaches to show more defined alterations in multiple lysosomal proteases, cytoskeletal proteins and protein translational components. Changes in the latter two protein categories are consistent with the reported biology of LRRK2. For example, LRRK2 was shown to bind tubulin directly (21), influence actin dynamics (40) and may regulate phosphorylation of the microtubule binding protein tau (41–46). Similarly, overexpression of proteins that regulate translation, including 4EBP1 (25, 47) and RPS15 (48), can mitigate toxic effects of mutant LRRK2. Overall, the broad range of proteins that are differentially regulated in our proteomics analysis suggests that endogenous LRRK2 affects multiple proteins in three major categories.

This study suggests that loss of Lrrk2 influences lysosomal, cytoskeletal and protein translation and that defective intracellular protein trafficking is the primary cause. We were able to show that localization of CI-M6PR is altered in LRRK2-KO cells, suggesting inherent alterations in trafficking in these cells. Interestingly, we find greater colocalization between CI-M6PR and cathepsin D. This could indicate either that cells are increasing the rate of trafficking to the lysosome or are failing to recycle CI-M6PR after delivery. As LRRK2 phosphorylates multiple members of the Rab family of small GTPases (49–51) one potential testable hypothesis that emerges from these observations is that knockout cells and tissues upregulate protein trafficking pathways to compensate for loss of Lrrk2-dependent Rab
phosphorylation (52, 53). It is also possible that the role of LRRK2 in the membrane trafficking pathways here studied is not mediated simply by its kinase activity but by other functional protein interaction domains such as the GTPase Roc-COR domain which seems involved in retrograde trafficking via downstream Rab GTPases such as Rab29 (54). In addition, LRRK2 could play a scaffolding role along microtubules, helping the formation of signaling complexes involved in membrane trafficking (21).

The distinction between specific regulation of individual proteins and broad alterations in categories of biologically related molecules is important as it suggests some of the observed changes may be compensatory responses to loss of Lrrk2. Supporting this interpretation, our data shows that differences between genotypes increase slowly over several months then tend to diminish partially with age, consistent with prior data suggesting complex biphasic responses with aging in LRRK2-KO animals (18). We therefore propose that Lrrk2 is involved in multiple cellular pathways and that, to compensate for lack of Lrrk2, there are compensatory and co-ordinated responses in the same pathways.

The relevance of this detailed study in brain and kidneys in loss of function and gain of kinase function models lies first in the identification of novel categories of proteins affected by loss of Lrrk2. These findings lay emphasis on the concept that kinase inhibitors might affect several intracellular pathways accumulatively over time. Second, the lack of concordance in proteomic changes between LRRK2-KO and the G2019S knock-in animals supports prior data that the mutations in Lrrk2 are pathogenic due to gain of function rather than having dominant negative effects.

Overall, the current data shed light on multiple protein networks affected by loss of LRRK2 in early stages of mouse development and demonstrates the utility of unbiased approaches to explore in vivo effects of gene manipulation.

**Materials and Methods**

**Animals**

Experiments using animals were conducted in compliance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The specific experiments performed in this study were approved by the Institutional Animal Care and Use Committees of the US National Institute on Aging.
(Animal study protocol number 463-LNG-2018). Animal experiments performed at UCL were approved by
the UCL Ethics Committee and by the home office as detailed in the relevant project license 80/2486 (KH).
LRRK2-KO mice (55) were generously provided by Huaibin Cai, NIA. LRRK2 G2019S knock-in mice
were generated as described previously (56). For proteomics experiments and for validation by western
blotting, age-matched wild type, homozygous LRRK2-KO mice and heterozygous knock-in mice, each
bred on a C57BL/6J background, were euthanized by cervical dislocation. For additional biological
validation of the effects of age on protein expression, we generated separate cohorts of wild type and
LRRK2-KO mice. From each animal, one kidney was immediately frozen in dry ice while the other was
fixed in 4% PFA in PBS for histological analysis. Brain hemispheres were separated and cortex, striatum
and hippocampus were dissected and frozen in dry ice.

Kidney sample preparation

For iTRAQ proteomic experiments, frozen kidneys dissected from one-year-old mice were homogenized
using Dounce homogenizers in isolation buffer containing 0.225M mannitol, 0.05M sucrose, 0.0005M
HEPES, 1mM EDTA. The homogenate was centrifuged at 2000xg for 3min at 4°C and the supernatant then
collected in a separate tube and centrifuged at 12000xg for 8min at 4°C. The supernatant was then
centrifuged at 100,000xg for 30min at 4°C and the resulting 10K supernatant and pellet fractions retained.
The 10K pellets were resuspended in iTRAQ compatible buffer (0.3M HEPES, 2% CHAPS, 1mM EDTA).
Total kidney homogenates for immunoblot validation of additional cohorts were prepared in lysis buffer
(20mM Tris HCl, 1% NP40, 150mM NaCl, 1mM EDTA, 10% glycerol), with protease inhibitor cocktail
tablet (Roche) and Halt phosphatase inhibitor (Thermo Scientific) added immediately before use. Protein
concentrations were determined using 660nm protein assay reagent (Pierce) using bovine serum albumin as
a standard reference.

Primary kidney cells preparation

For primary kidney cell preparation, kidneys from 8-9 month-old mice were collected and washed in cold
HBSS (Hank Balances Salt Solution, Gibco) to remove residual blood. Renal fibrous capsule, connective
tissue and renal medulla were removed. Kidney cortical tissue was dissected and mechanically minced
using scalpels. Tissue homogenates were then transferred into 50ml falcon tubes containing HBSS with 1mg/mL collagenase IV (Invitrogen) to allow digestion at 37°C for 30min. Digested kidney fragments were then passed through a 100 μm sieve in another falcon tube to remove fibrous tissue. The sieve was washed in HBSS and the cell suspension centrifuged at 1200rpm for 5min twice. Finally, the cell pellet was resuspended in complete culture media: DMEM/F12 1:1 media (Invitrogen) containing 5% FBS, 10 ng/mL Epidermal Growth Factor (EGF, Invitrogen), 1% penicillin/streptomycin (Invitrogen), 1% L-glutamine (Invitrogen), 50mM hydrocortisone (Sigma Aldrich), 5 μg/mL insulin (Invitrogen), 5 μg/mL transferrin (Sigma Aldrich) and 50nM sodium selenite (Sigma Aldrich). Cells were cultured in 75cm² plastic flasks with complete culture medium at 37°C under 5% CO₂ in a humidified atmosphere.

Isobaric Tag for Relative and Absolute Quantitation (iTRAQ) Labelling

For iTRAQ experiments, we modified procedures we previously reported for mouse brain samples (57). Kidney 10K supernatants and pellets from five wild type and five LRRK2-KO samples were analyzed in two separate experiments for a total of four iTRAQ runs (Figure 1). A pooled reference sample was made by combining 40 μg of each of the wild type samples together. The concentration of each sample was adjusted to 1 μg/μl with iTRAQ buffer (0.3M HEPES, 2% CHAPS, 1mM EDTA). Samples were treated with 2 μl of tris 2-carboxyethyl phosphine for 60min at 60°C and subsequently alkylated with 1 μl of methyl methanethiosulfonate for 20min at RT. The mass spectrometry grade trypsin (Promega) was used to digest the samples. The first digestion was carried out overnight at 37°C with a trypsin:protein ratio of 1:100 (w/w). The samples were digested again with a trypsin:protein ratio of 1:100 (w/w) for 8hr at 37°C. Before addition to samples, iTRAQ 8-plex reagents were dissolved in 150 μl of isopropanol and vortexed. Each sample mixture was then labeled for 3h at RT with the appropriate iTRAQ reagent, and labeled peptide mixtures were combined. Samples were desalted using an Oasis HLB 200mg cartridge. Fractionation of iTRAQ labeled peptides by liquid chromatography (LC) and subsequent tandem mass spectrometry (MS/MS) analysis of the fractions were performed as previously described (57).

Western Blotting
Equal amounts of total protein from each preparation were separated using SDS-PAGE and transferred into nitrocellulose membranes. After 1hr blocking with Odyssey Blocking Buffer (LI-COR), membranes were probed overnight with primary antibodies (listed in the following section). Incubation with IRDye-labeled 800CW goat anti-rabbit and goat anti-mouse secondary antibodies (LI-COR, 1:15,000) was performed for 1 hr at RT. Protein bands of interest were visualized with Odyssey CLx Infrared Imaging Studio. Band intensity was quantified using LI-COR Image Studio software.

**Antibodies**

The following antibodies used for immunoblot were diluted in a 1:1 mix of Odyssey Blocking Buffer (LI-COR) and TBS containing 0.1% (v/v) Tween 20: rabbit polyclonal antibody to cathepsin D (Millipore, 219361, 1:1000), goat polyclonal antibody to cathepsin D C-20 (Santa Cruz, sc-6486, 1:200), rabbit polyclonal antibody to legumain (Abcam, ab125286, 1:1000), mouse monoclonal antibody to gephyrin (Synaptic System, 147 111, 1:2000), mouse monoclonal antibody to β-actin (Sigma, A5316, 1:10,000), rabbit polyclonal antibody to α/β-tubulin (Cell Signaling, 2148, 1:1000), mouse monoclonal antibody to acetylated-tubulin (Sigma, T7451, 1:1000), rabbit polyclonal antibody to coronin 1C (Proteintech, 14749-1-AP, 1:1000), mouse monoclonal antibody to NAA15 (LSBio, LS-C342562, 1:1000), rabbit polyclonal to EEF1G (Abcam, ab72368, 1:1000), mouse monoclonal to HNRNPK antibody (Abcam, ab23644, 1:1000) and rabbit polyclonal to LC3B (Abcam, ab51520, 1:2000). The following antibodies were used for immunohistochemistry: rabbit polyclonal antibody to cathepsin D (Millipore, 219361, 1:200), goat polyclonal antibody to cathepsin D C-20 (Santa Cruz, sc-6486, 1:200), rat monoclonal antibody to LAMP1 (1D4B) (Abcam, ab25245, 1:200), mouse monoclonal to mannose-6-phosphate receptor cation independent (CI-M6PR) antibody [2G11] (Abcam, ab2733, 1:200), rabbit monoclonal to CI-M6PR [EPR6599] (Abcam, ab124767, 1:200).

**Histological analysis**

Kidneys were fixed post-mortem by immersion in 4% PFA overnight and then transferred to PBS with 30% sucrose and 0.05% sodium azide for 24h. Tissues were then frozen and 40 μm sections cut using a Leica CM1900 cryostat. After three 5min washes in PBS, sections were blocked at room temperature for 1h in
blocking buffer (0.3% Triton, 1% BSA, 1% donkey serum in PBS). The same buffer was used for the primary antibody incubation overnight at 4°C with gentle shaking. Sections were then washed 3 times in PBS for 10 min and incubated with Alexa Fluor secondary antibodies (donkey anti-rabbit and donkey anti-goat, 1:500) for 2 h at room temperature. After three 10 min washes in PBS, sections were mounted on glass slides using Prolong Gold mounting media (Life Technologies).

*Immunocytochemistry*

Primary kidney cells were seeded in poly-D lysine coated coverslips and fixed in 4% PFA for 20 min. Cells were then incubated for 1 h with blocking buffer (0.1% Triton, 5% FBS in PBS) and the same buffer was used for the following antibody incubations. Primary antibody incubation was performed for 2 h at RT. Cells were then washed 3 times in PBS prior to secondary antibody incubation for 1 h with Alexa Fluor antibodies diluted 1:500. Each coverslip was then mounted on a microscope slide using Prolong mounting media (Sigma) and left to dry overnight at RT.

*Confocal microscopy*

Confocal microscopy was performed using a Zeiss LSM 710 (Carl Zeiss). Fluorescence was excited by the 405 nm, 488 nm and 595 nm laser lines of Argon, diode and Helium/Neon lasers. Images were taken with a 40 x 1.3 numerical aperture (NA) or 63 x 1.4 NA oil objective. Images were collected using Zen software (Carl Zeiss) and prepared using Fiji (NIH). Representative images are shown without any additional processing. Airyscan imaging was performed using a Zeiss 880 outfitted with an Airyscan module. Data was collected using a 63 x 1.4 NA objective and immersion oil optimised for 30°C (Carl Zeiss). Colors were collected sequentially to minimize crosstalk, and Airyscan processing was performed using the Airyscan module in the commercial ZEN software package (Carl Zeiss).

*High content imaging*

Cells that had been fixed and immunostained for confocal analysis were subsequently analyzed using a Thermo Scientific Cellomics ArrayScan VTi HCS Reader. Plates were imaged using a 20x objective and analyzed using the Spot Detector bioapplication for % of cells with cathepsin D-positive spots from total
number of cells, average spot area and intensity of staining per cell.

*Image quantification*

Quantification was performed by an individual blinded to genotype using a combination of custom algorithms in Fiji (NIH), Imaris (Biplane, Inc.) and in NIS Elements analysis software. To assist the algorithm in correctly identifying the structures, background subtraction was performed by subtracting a flat numerical value from all channels in all images. The number of cathepsin D-positive vesicles was quantified using a spot detection algorithm in Imaris, thresholds were decided from several images and then applied to all images simultaneously. To normalize the number of cathepsin D-positive vesicles to the number of cells in the tissue section, the nuclei were quantified using a surface detection algorithm using the method of marching squares.

*Quantitative real-time polymerase chain reaction (qRT-PCR)*

Isolation of total RNA, reverse transcription and qRT-PCR were performed as previously described with few changes (58). Total RNA from primary cultured mouse kidney cells and mouse kidney tissue was isolated and purified with the RNeasy Mini Kit (QIAGEN). RNA was reverse transcribed with the SuperScript® III First-Strand Synthesis System (Invitrogen) and qPCR of diluted cDNA was carried out on an AriaMx Realtime PCR System (Agilent Technologies) using iTaq™ Universal SYBR® Green Supermix (Bio-Rad Laboratories) for a total reaction volume of 20 µl. Oligo 6.0 software (MedProbe) served as program to select intron-spanning primers targeting the *mus musculus* cathepsin D gene (NM_009983.2; 330-forward 5'-GCCGCAGTGGTTTCAAG-3'; 479-reverse 5'-TGAGCGTGAGTGGATGTCAAC-3'; amplification product: 169bp). Optimized primers for the two housekeeping reference genes, GAPDH and β-actin, have been used as published earlier (58): GAPDH: NM_008084; 205-forward 5'-GCCAATTTCAACGCACAA-3'; 337-reverse 5'-CACCAGTCGGTCCACGAG-3'; amplification product: 141 bp; β-actin: NM_007393; forward 5'-GCCAACCCTTGAAAAGATGAC-3'; reverse 5'-GGCGTGAGGAGGAGCATAG-3'. In order to verify the specificity of the PCR products gel electrophoresis, melting curve analysis and ‘-RT’ (reverse transcriptase) as well as water control PCR reactions were conducted. Calculation of relative expression levels for cathepsin D in LRRK2 knockout
versus wild type samples was determined with the $\Delta \Delta C_t$ method. Statistical analysis was done using nonparametric Mann-Whitney test.

**Bioinformatics and Statistical analyses**

In all experiments, n represents the number of individual animals included in an experiment. Both male and female mice were used. Although animals were not treated and therefore not randomized into treatment groups, iTRAQ proteomics experiments were performed with animals of both genotypes included across different proteomics runs (Figure 1A). In all statistical analyses, a preset value of alpha=0.05 was used to reject the null hypothesis of no difference, with multiple test correction as appropriate.

iTRAQ labeled peptide identification and quantitation was performed using Mascot (59) from Xcalibur RAW files with parameters and thresholds for peak picking as previously described (57). Peptide identification was performed using the Mascot Server (version 2.5) to identify homologous peptides in the Sprot Mouse Database (Uniprot Proteome ID: UP000000589) with iTRAQ8plex (N-term) and iTRAQ8plex (K) set as fixed modifications and Methylthio (C), Oxidation (M) and iTRAQ8plex (Y) set as variable modifications. Only unique peptides were used to identify and calculate protein ratios. The iTRAQ label intensity for each sample was divided by the intensity of the pooled reference to obtain peptide ratios, and subsequently normalized so that the median ratio for each peptide was 1 for the wild type animals. Missing data points were imputed using $k$-nearest neighbours in the “impute” package in R within each sample type and series only where the number of missing values was less than five (60). Statistical inferences were assessed by Welch’s t-test, allowing for unequal variance between groups, followed by the Benjamini-Hochberg false-discovery rate correction for multiple testing (61). Graphs are plotted as raw p values, but reported as significant only if the adjusted $p<0.05$. Evaluation of Gene Ontology term enrichments was performed using gProfileR within R (62). Protein interaction networks were acquired from the IntAct database (http://www.ebi.ac.uk/intact/) and visualized using Cytoscape.

Data was plotted using Prism 6 (Graphpad) or R (https://www.rstudio.com/) and displayed as means and standard error of the mean (SEM). For validation experiments, student’s t-test was used to determine differences between data consisting of two groups and Analysis of Variance (ANOVA) with Bonferroni correction.
post-hoc tests for multiple group comparisons. Differences between groups were plotted on graphs using the following codes: * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001.

Acknowledgements

This research was supported in part by the Intramural Research Program of the National Institute of Health, National Institute on Aging and National Institute on Neurological Disorders and Stroke (to MRC) and the Medical Research Council [MR/M00676X/1 to KH]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We thank Dr. Huaibin Cai, NIA, for the gift of LRRK2-KO mice and David C Gershlick for critically reading the manuscript.

Conflict of Interest Statement

The authors declare no conflict of interest.
References


49. Steger, M., Tonelli, F., Genta Ito, Paul Davies, Matthias Trost, Melanie Vetter, Stefanie Wachter, Esben


Legends to Figures

**Figure 1. Proteomic analysis of LRRK2 knockout kidneys.** (A) Tables of the iTRAQ runs: 10K supernatants and 10K pellets for two independent experiments. Schematic experimental plan including sample preparation, representative iTRAQ labelling, peptide fractionation via LC followed by tandem MS. (B) Immunoblots from kidney enriched fractions for endo-lysosomal markers Rab7 and LAMP1, and for the cytosolic marker GAPDH (n=4). Volcano plots of the 504 proteins quantified in the 10K supernatants (C) and of the 1187 proteins quantified in the 10K pellets (D) (n=5, Welch T-test, p values corrected using Benjamini-Hochberg post hoc test). Heat maps of significant genes differently regulated in 10K supernatants (E) and 10K pellets (F). WT = wild type, KO = LRRK2-KO, S = 10K supernatant, P = 10K pellet.

**Figure 2. Altered gene ontology pathways in LRRK2 knockout kidneys.** Map of dysregulated gene ontology pathways was generated using the Enrichment map Cytoscape plug-in. Analysis was performed with gProfileR package using a false discovery rate correction. Cellular component (CC), biological process and molecular function have been depicted for each gene set. Node size corresponds to the number of genes in each GO term. Only GO terms ranging between 10-5000 were included in this analysis. Node color corresponds to which gene set each enrichment is derived from with shading being proportional to P value (cut off, ≤ 0.05). Edges signify significant overlap between GO terms using a cut off of 0.5 similarity coefficient, darker edges indicate greater overlap between terms.

**Figure 3. Proteomic analysis of LRRK2 G2019S knock-in kidneys.** Volcano plots of the 729 proteins quantified in the 10K supernatants (A) and of the 785 proteins quantified in the 10K pellets (B) (n=5, Welch T-test, p values corrected using Benjamini-Hochberg post hoc test). Heat maps of detected genes (with p value < 0.05 before correction) in 10K supernatants (C) and 10K pellets (D). Correlation of fold-changes between G2019S-KI and LRRK2-KO, in 10K supernatants (E) and 10K pellets (F).
Figure 4. **Validation of iTRAQ proteomics results.** (A) Immunoblots for LRRK2 and the iTRAQ hits of interest normalized for the loading control \( \beta \)-actin in the 10K supernatants and in the 10K pellets (B). Quantifications of immunoblots from cytosolic (C) and microsomal (D) enriched fractions. (E) Comparison of the log2 fold expression (KO/WT) using the iTRAQ data compared to the immunoblot data.

Figure 5. **Biological validation of iTRAQ results across aging cohorts.** Immunoblots for the iTRAQ proteins of interest using kidney homogenates from P0 (A), 1 month-old (B), 9 month-old (C), 12-month-old (D) LRRK2-KO and control mice. Plots indicating the differences in the iTRAQ candidate lysosomal hydrolases (E), translational regulators (F) and cytoskeletal-associated proteins (G) quantified from the immunoblots, between aging cohorts (Supplementary figure for additional immunoblot quantification graphs).

Figure 6. **Histological characterization of LRRK2 knockout kidneys.** (A) Confocal imaging of wild type, LRRK2-KO (5-6 month-old, n=3) for cathepsin D (rabbit polyclonal antibody, AlexaFluor 568 secondary antibody), LAMP1 (rat monoclonal antibody, AlexaFluor 488 secondary antibody) and DAPI staining. Scale bar: 20 \( \mu \)m. (B) Representative Airy scan images of the same wild type and LRRK2-KO kidneys for cathepsin D, LAMP1 and DAPI staining. Scale bar: 10 \( \mu \)m. (C) Confocal imaging of the same wild type and LRRK2-KO kidneys for cathepsin D (goat polyclonal antibody, AlexaFluor 568 secondary antibody) and M6PR (rabbit monoclonal antibody, AlexaFluor 488 secondary antibody) and DAPI staining. Scale bar: 20 \( \mu \)m. (D) Quantification of cathepsin D and LAMP1 colocalization in the kidney sections shown in panel (A). (E) Quantification of cathepsin D and M6PR colocalization in the kidney sections shown in (C). Data points represent the Pearson’s correlation coefficient from at least 5 images per animal, with multiple cells per image, n=3 mice per genotype. (F) Number of cathepsin D punctae per nuclei and area (\( \mu \) m\(^2\)) of cathepsin D (G) and LAMP1 (H) positive vesicles. (I) Immunoblot analysis of WT and LRRK2-KO kidney lysates (12 month-old total homogenates, n=5) using CI-M6PR and LAMP1 antibodies. Quantifications of CI-M6PR (J) and of LAMP1 (K) immunoblots normalized for the loading control \( \beta \)-actin.
Figure 7. Impaired trafficking of mannose-6-phosphate receptor in LRRK2 knockout cells.

(A) Cellomics representative images of wild type and LRRK2-KO primary kidney cells. (B) Quantifications of percentage of cells with cathepsin D structures, average spot area (μm²) and average intensity counted using the spot detector bioapplication of the Cellomics arrayscan. (C) Immunoblots for cathepsin D in total homogenates from LRRK2-KO and control primary kidney cells. (D) Immunoblot quantifications of cathepsin D precursor and mature forms. (E) Representative confocal images of LRRK2-KO and wild-type primary kidney cells stained in red for cathepsin D (anti-rabbit, AlexaFluor 568 secondary antibody), in green for M6PR (anti-mouse, Alexa 488 secondary antibody). Nuclei in blue were stained with Hoechst. Scale bar = 20 μm (5 μm for magnification). (F) Quantifications of percentage per cell, average area and average intensity of M6PR punctae in LRRK2-KO and wild-type primary kidney cells. (G) Pearson’s correlation coefficient measured by manually quantifying 50 cells after confocal imaging and (H) overlap area (μm²) measured by high content image analysis.
Figure 1. Proteomic analysis of LRRK2 knockout kidneys. (A) Tables of the iTRAQ runs: 10K supernatants and 10K pellets for two independent experiments. Schematic experimental plan including sample preparation, representative iTRAQ labelling, peptide fractionation via LC followed by tandem MS. (B) Immunoblots from kidney enriched fractions for endo-lysosomal markers Rab7 and LAMP1, and for the cytosolic marker GAPDH (n=4). Volcano plots of the 504 proteins quantified in the 10K supernatants (C) and of the 1187 proteins quantified in the 10K pellets (D) (n=5, Welch T-test, p values corrected using Benjamini-Hochberg post hoc test). Heat maps of significant genes differently regulated in 10K supernatants (E) and 10K pellets (F). WT = wild type, KO = LRRK2-KO, S = 10K supernatant, P = 10K pellet.
Figure 2. Altered gene ontology pathways in LRRK2 knockout kidneys. Map of dysregulated gene ontology pathways was generated using the Enrichment map Cytoscape plug-in. Analysis was performed with gProfileR package using a false discovery rate correction. Cellular component (CC), biological process and molecular function have been depicted for each gene set. Node size corresponds to the number of genes in each GO term. Only GO terms ranging between 10-5000 were included in this analysis. Node color corresponds to which gene set each enrichment is derived from with shading being proportional to P value (cut off, ≤ 0.05). Edges signify significant overlap between GO terms using a cut off of 0.5 similarity coefficient, darker edges indicate greater overlap between terms.

22x30mm (600 x 600 DPI)
Figure 3. Proteomic analysis of LRRK2 G2019S knock-in kidneys. Volcano plots of the 729 proteins quantified in the 10K supernatants (A) and of the 785 proteins quantified in the 10K pellets (B) (n=5, Welch T-test, p values corrected using Benjamini-Hochberg post hoc test). Heat maps of detected genes (with p value < 0.05 before correction) in 10K supernatants (C) and 10K pellets (D). Correlation of fold-changes between G2019S-KI and LRRK2-KO, in 10K supernatants (E) and 10K pellets (F).
Figure 4. Validation of iTRAQ proteomics results. (A) Immunoblots for LRRK2 and the iTRAQ hits of interest normalized for the loading control β-actin in the 10K supernatants and in the 10K pellets (B). Quantifications of immunoblots from cytosolic (C) and microsomal (D) enriched fractions. (E) Comparison of the log2 fold expression (KO/WT) using the iTRAQ data compared to the immunoblot data.
Figure 5. Biological validation of iTRAQ results across aging cohorts. Immunoblots for the iTRAQ proteins of interest using kidney homogenates from P0 (A), 1 month-old (B), 9 month-old (C), 12-month-old (D) LRRK2-KO and control mice. Plots indicating the differences in the iTRAQ candidate lysosomal hydrolases (E), translational regulators (F) and cytoskeletal-associated proteins (G) quantified from the immunoblots, between aging cohorts (Supplementary figure for additional immunoblot quantification graphs).
Figure 6. Histological characterization of LRRK2 knockout kidneys. (A) Confocal imaging of wild type, LRRK2-KO (5-6 month-old, n=3) for cathepsin D (rabbit polyclonal antibody, AlexaFluor 568 secondary antibody), LAMP1 (rat monoclonal antibody, AlexaFluor 488 secondary antibody) and DAPI staining. Scale bar: 20µm. (B) Representative Airy scan images of the same wild type and LRRK2-KO kidneys for cathepsin D, LAMP1 and DAPI staining. Scale bar: 10 µm. (C) Confocal imaging of the same wild type and LRRK2-KO kidneys for cathepsin D (goat polyclonal antibody, AlexaFluor 568 secondary antibody) and M6PR (rabbit monoclonal antibody, AlexaFluor 488 secondary antibody) and DAPI staining. Scale bar: 20µm. (D) Quantification of cathepsin D and LAMP1 colocalization in the kidney sections shown in panel (A). (E) Quantification of cathepsin D and M6PR colocalization in the kidney sections shown in (C). Data points represent the Pearson’s correlation coefficient from at least 5 images per animal, with multiple cells per image, n=3 mice per genotype. (F) Number of cathepsin D punctae per nuclei and area (µm²) of cathepsin D (G) and LAMP1 (H) positive vesicles. (I) Immunoblot analysis of WT and LRRK2-KO kidney lysates (12 month-old total homogenates, n=5) using CI-M6PR and LAMP1 antibodies. Quantifications of CI-M6PR (J) and of LAMP1 (K)
immunoblots normalized for the loading control β-actin.

22x30mm (600 x 600 DPI)
Figure 7. Impaired trafficking of mannose-6-phosphate receptor in LRRK2 knockout kidney cells.

(A) Cellomics representative images of wild type and LRRK2-KO primary kidney cells. (B) Quantifications of percentage of cells with cathepsin D structures, average spot area (µm²) and average intensity counted using the spot detector bioapplication of the Cellomics arrayscan. (C) Immunoblots for cathepsin D in total homogenates from LRRK2-KO and control primary kidney cells. (D) Immunoblot quantifications of cathepsin D precursor and mature forms. (E) Representative confocal images of LRRK2-KO and wild-type primary kidney cells stained in red for cathepsin D (anti-rabbit, AlexaFluor 568 secondary antibody), in green for M6PR (anti-mouse, Alexa 488 secondary antibody). Nuclei in blue were stained with Hoechst. Scale bar = 20 µm (5 µm for magnification). (F) Quantifications of percentage per cell, average area and average intensity of M6PR puncta in LRRK2-KO and wild-type primary kidney cells. (G) Pearson’s correlation coefficient measured by manually quantifying 50 cells after confocal imaging and (H) overlap area (µm²) measured by high content image analysis.